Diabetic Peripheral Neuropathy Market size in the 7MM was approximately USD 2,740 million in 2022, estimated DelveInsight

DelveInsight's "Diabetic Peripheral Neuropathy Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Diabetic Peripheral Neuropathy, historical and forecasted epidemiology as well as the Diabetic Peripheral Neuropathy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Diabetic Peripheral Neuropathy Market with DelveInsight's In-Depth Report @ Diabetic Peripheral Neuropathy Market Size [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Diabetic Peripheral Neuropathy Market Report

* In 2023, the highest number of type-specific cases of diabetic neuropathy were observed for peripheral diabetic neuropathy in the 7MM.
* The total prevalent cases of diabetic peripheral neuropathy in the 7MM were around 34,000,000 cases in 2023 out of which the highest prevalent cases of this disease were seen in the United States.
* Among EU4 and the UK, Germany accounted for the highest cases of the total prevalent cases of diabetic neuropathy, whereas Spain accounted for the least number of cases.
* The US accounted for nearly 50% of total treated cases in 2023, which is expected to increase by 2034.
* The leading Diabetic Peripheral Neuropathy Companies such as Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals, and others.
* Promising Diabetics Peripheral Neuropathy Therapies such as LY3556050, Engensis, Suzetrigine, Pregabalin , and others.

Stay ahead in the Diabetic Peripheral Neuropathy Therapeutics Market with DelveInsight's Strategic Report @ Diabetic Peripheral Neuropathy Market Outlook [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Peripheral Neuropathy Epidemiology Segmentation in the 7MM

* Diabetic Peripheral Neuropathy Prevalent Cases
* Diabetic Peripheral Neuropathy Treated Cases
* Diabetic Peripheral Neuropathy Prevalent Cases of Painful

Download the report to understand which factors are driving Diabetic Peripheral Neuropathy epidemiology trends @ Diabetic Peripheral Neuropathy Prevalence [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Peripheral Neuropathy Marketed Drugs

* QUTENZA (capsaicin): Grunenthal/Averitas Pharma

QUTENZA (capsaicin), developed by Grunenthal and Averitas Pharma, is an 8% topical system that contains capsaicin in a localized dermal delivery system. Capsaicin is an agonist for the transient receptor potential vanilloid 1 receptor (TRPV1), which is an ion channel-receptor complex expressed on nociceptive nerve fibers in the skin. Topical administration of capsaicin causes an initial enhanced stimulation of the TRPV1-expressing cutaneous nociceptors that may be associated with painful sensations. In July 2020, Grunenthal's US subsidiary Averitas Pharma received US FDA approval for a QUTENZA (capsaicin) 8% patch for treating neuropathic pain associated with Diabetic Peripheral Neuropathy of the feet in adults.

* TARLIGE (mirogabalin besylate): Daiichi Sankyo

TARLIGE (mirogabalin besylate) is an orally administered gabapentinoid developed by Daiichi Sankyo for the treatment of peripheral neuropathic pain, including diabetic Peripheral Neuropathic pain and postherpetic neuralgia. In January 2019, Daiichi Sankyo announced the approval of TARLIGE for marketing in Japan for the treatment of Diabetic Peripheral Neuropathy and expects the drug to benefit patients in Japan by providing a new therapeutic option for the treatment of Peripheral Neuropathy Pain.

Diabetic Peripheral Neuropathy Emerging Drugs

* Engensis (VM202): Helixmith

Engensis (VM202), developed by Helixmith is a DNA-based drug designed to produce two isoforms of HGF (hepatocyte growth factor), HGF728 and HGF723. When VM202 is delivered to the affected area by a single intramuscular injection, this drug enters a small portion of the surrounding muscle cells. In the case of Diabetic Peripheral Neuropathy, it has the potential to reverse the underlying cause of neuropathy through an angio-neurorestorative effect, without simply managing the pain. This drug is currently in Phase III developmental stage and has been granted RMAT (Regenerative Medicine Advanced Therapy) designation by the US FDA in 2018.

* Suzetrigine (VX-548): Vertex Pharmaceuticals

VX-548 being developed by Vertex Pharmaceuticals is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the treatment of pain and multiple pain indications including acute pain, and neuropathic pain. It is currently in Phase III development stage.

Get In-Depth Knowledge on Diabetic Peripheral Neuropathy Market Trends and Forecasts with DelveInsight @ Diabetic Peripheral Neuropathy Treatment Market [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Diabetic Peripheral Neuropathy Market Outlook

Treatment modalities focus on optimized diabetic management and symptomatic relief. Glycemic control is the first step in the approach to disease management and has been shown to improve the occurrence of falls and the presence of foot ulcers. The three main principles of treatment for peripheral neuropathy are glycemic control, foot care, and pain management. The prescription medicines commonly used for managing diabetic peripheral neuropathy pain include Gabapentin and Pregabalin, Tricyclic Antidepressants (TCAs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs), and Opioids. Other Alternatives include Antiseizure Medications like carbamazepine or lamotrigine.

Diabetic Peripheral Neuropathy Drugs Uptake

Suzetrigine (VX-548), under development by Vertex Pharmaceuticals, holds promise as a potential game-changer in the treatment landscape of diabetic peripheral neuropathy. Positioned as an oral, selective NaV1.8 inhibitor, Suzetrigine boasts high selectivity for NaV1.8 over other NaV channels, enhancing its therapeutic potential. Its Phase III development stage underscores its advancement towards market entry. The oral route of administration offers a distinct advantage, ensuring ease of uptake for patients compared to alternative pipeline drugs. Moreover, Suzetrigine's mechanism of action aligns with addressing neuropathic pain effectively.

Unlock Strategic Insights with DelveInsight's Comprehensive Diabetic Peripheral Neuropathy Market Report @ Diabetic Peripheral Neuropathy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/diabetic-peripheral-neuropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Diabetic Peripheral Neuropathy Market Report

* Coverage- 7MM
* Diabetic Peripheral Neuropathy Companies- Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals, and others.
* Diabetics Peripheral Neuropathy Therapies- LY3556050, Engensis, Suzetrigine, Pregabalin, and others.
* Diabetic Peripheral Neuropathy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Diabetic Peripheral Neuropathy Unmet Needs, KOL's views, Analyst's views, Diabetic Peripheral Neuropathy Market Access and Reimbursement

Table of Content

1 Key Insights

2 Report Introduction

3 Executive Summary

4 Key Events

5 Epidemiology and Market Forecast Methodology

6 Diabetic Peripheral Neuropathy Market Overview at a Glance

7 Disease Background and Overview

8 Treatment and Management

9 Epidemiology and Patient Population of Diabetic Peripheral Neuropathy in the 7MM

10 Patient Journey

11 Marketed Therapies

Full list of marketed drugs will be provided in the report

12 Emerging Therapies

Full list of emerging drugs will be provided in the report

13 Diabetic Peripheral Neuropathy: 7MM Market Analysis

14 Unmet Needs

15 SWOT Analysis

16 KOL Views

17 Market Access and Reimbursement

18 Appendix

19 DelveInsight Capabilities

20 Disclaimer

21 About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=diabetic-peripheral-neuropathy-market-size-in-the-7mm-was-approximately-usd-2740-million-in-2022-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity



This release was published on openPR.